Back to Newsroom

Catalyst Pharmaceuticals Announces Proposed Settlement of Pending Securities Class Action Lawsuit

CORAL GABLES, Fla., Nov. 4, 2014 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals or the Company), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it has entered into a memorandum of understanding (“MOU”) to settle its pending class action securities lawsuit.

Click here to read more